Conventional synthetic DMARDs are strongly recommended if there is an inadequate response to scheduled NSAIDs and/or IAGCs for active oligoarthritis. Methotrexate is conditionally recommended as a preferred agent over leflunomide, sulfasalazine, or hydroxychloroquine (in that order). Despite an absence of comparator trials, methotrexate is the preferred agent, given the preponderance of evidence showing its long-term safety and efficacy in children With regard to the route of administration of